Completed PHASE1 INTERVENTIONAL 4-arm NCT02495246

A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV

A Phase I, Safety and Immunogenicity Trial of the Heterologous Prime-boost Regimen Combining the Monovalent Zaire Ebola Viral Vector Candidates ChAd3-EBO-Z and Ad26.ZEBOV in Healthy UK Adults

Sponsor: University of Oxford

Conditions Ebola Virus Disease

Interventions Ad26.ZEBOV ChAd3-EBO-Z

Updated 7 times since 2017 Last updated: Apr 10, 2018 Started: Sep 21, 2015 Primary completion: Aug 22, 2017 Completion: Aug 22, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02495246, this PHASE1 trial focuses on Ebola Virus Disease and remains completed. Sponsored by University of Oxford, it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
May 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

Jul 2017 — May 2018 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Jul 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Oxford

Data source: University of Oxford

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oxford, United Kingdom